
Icelandic orcas have been including baby pilot whales in their groups – but scientists aren't sure why
Scientists watched two encounters between killer whales and weeks-old baby pilot whales in 2022 and 2023 in a new paper published in Ecology and Evolution, and examined an earlier case in 2021, to come up with three possible reasons for the unusual behaviour.
Firstly, it could have been predatory behaviour, but the researchers noted the groups of whales in question largely eat fish only. Another reason was for play, or for hunting training.
But the third possible reason could be that the orcas were caring for the calves, and had potentially adopted the pilot whales.
But the researchers, led by Cherine Baumgartner, stressed they had not seen the beginning or end of the interactions, and more close observation would be needed to unpick what exactly was happening between the two whale species.
Orcas are apex ocean predators, and normally only interact with other species to hunt them, the researchers said.
But researchers in 2022 spotted a group of killer whales travelling with a very young pilot whale calf.
At times, the researchers notice a killer whale keeping its head very close to the calf's body, 'seemingly nudging the calf towards the surface with the pilot whale calf appearing to respond often with tail slapping'.
Then in 2023, a team noticed a different group of killer whales traveling with another very small pilot whale calf, which was repeatedly seen swimming near an adult female in an echelon position, which is a behaviour that has been seen in both aggressive context and more caregiving contexts. The calf was later seen being lifted out of the water by a killer whale.
The researchers said while the activity appeared to be 'playful', that doesn't mean play was the main reason for the orcas interacting with the pilot whale calves. A related potential explanation was practice hunting.
'Observations of a female and a juvenile swimming on either side of the pilot whale calf may indicate training exercises aimed at preventing prey from evading,' the researchers said.
'Such coordinated behaviour could serve as practice for herding techniques used during actual feeding, though this remains untested.'
The final possible explanation offered by researchers is that the orcas had potentially adopted the pilot whale calves, in what is called epimeletic behaviour or alloparental care.
'During our longer encounters … we observed behaviours that could be interpreted as caregiving, such as pushing the pilot whale calf from underneath - potentially to keep it afloat,' the paper said.
But they warned that all three encounters reported to date had been brief - a matter of hours, or less - and probably only showed part of a longer series of events.
One of the co-researchers told Scientific American that how the calves ended up with the killer whales to begin with, and what happened to them afterwards, were key questions.
'Was it lost or abandoned?' said Filipa Samarra, from the University of Iceland and the principal investigator at the Icelanding Orca Project. 'Or did the killer whales actively approach to take the calf away?'
Another key question is how many different orca groups have done similar things.
'So far, different killer whale groups have been involved in all three events reported, but we do not know how widespread this behaviour is within the population,' they said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
12 minutes ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.


The Independent
4 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.


BBC News
7 hours ago
- BBC News
Sellafield robotic arms to decommission nuclear gloveboxes
A development in robotic technology could be the answer to cleaning up hundreds of nuclear devices collected over in Cumbria, Europe's largest nuclear plant, has built up a stack of 700 gloveboxes - sealed containers with built in gloves that allow operators to handle radioactive are up to 60 years old, vary in size and shape and still contain contaminated materials like pipework and valves.A team of robotics experts has developed a dextrous mechanised arm that can be fitted inside an active nuclear glovebox to help tackle the challenging task of cleaning up and disposing of these devices. Known as the Risk Reduction of Glovebox Operations (RrOBO) project, it was developed in partnership with AtkinsRéalis, Cavendish Nuclear and Taylor Kightley Engineering."Removing hands from gloveboxes is a key challenge for the nuclear industry and we're proud to be helping to drive change and improve safety," said Robert Marwood, from AtkinsRé proved the robotic arm could successfully carry out a complex series of tasks safely, meaning the technology can now be deployed to legacy gloveboxes to accelerate decommissioning. A spokesman for Sellafield, which opened in 1947 and has the largest stockpile of radioactive plutonium in the world, said some of its older labs contained gloveboxes dating back decades, taking up space and posing "a potential hazard to workers and the environment"It started running a glovebox training facility this year to help meet demand for the spokesman said: "We'll need a pipeline of skilled glovebox operators for many years to come, but it's difficult work requiring high levels of dexterity and consistent standards."They added the nuclear industry nationally needed thousands of new gloveboxes to support "current and future missions in the decommissioning and defence sectors." Follow BBC Cumbria on X, Facebook, Nextdoor and Instagram.